Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis

Novartis has secured approval from the US Food and Drug Administration (FDA) for its Cosentyx (secukinumab) to treat active non-radiographic axial spondyloarthritis (nr-axSpA).